Smart Chemotherapy Gets Smarter: Advances in Antibody-drug Conjugates
Antibody-drug conjugates, or ADCs, have emerged as a significant class of cancer therapies over the past two decades. New...
Tag: Antibody-drug conjugates
Antibody-drug conjugates, or ADCs, have emerged as a significant class of cancer therapies over the past two decades. New...
Antibody-drug conjugates, or ADCs, are increasingly common cancer therapies. But what are they? How do they work? And how...
We highlight some of the many innovations showcased at the inaugural AACR Drug Discovery and Development (AACR D3) conference,...
The AACR D3 edition of “From the Bench” highlights cutting-edge approaches from the meeting that could shape the next...
The FDA issued 14 oncology approvals this quarter, including the first tumor-infiltrating lymphocyte therapy.
In part 3 of our 2024 Experts Forecast, AACR President-Elect Patricia M. LoRusso, DO, PhD (hc), FAACR, shares thoughts...
Guest Post by William G. Nelson, MD, PhD, Editor-in-Chief, Cancer Today Many argue that warfare metaphors, with winners and losers,...
Advances against cancer that make it to the clinic are a result of many years of hard work by...